Breakthrough Brain Tumour Treatment Doubles Survival in Clinical Trial

A new treatment for brain tumours has shown remarkable success in a major clinical trial. Researchers at The University of Texas MD Anderson Cancer Center tested a novel approach called tile-based radiation therapy (TBRT), which involves implanting radioactive tiles directly into the surgical cavity after tumour removal. The results reveal a significant drop in cancer recurrence and a doubling of survival rates compared to the current standard treatment. The trial, named ROADS, compared TBRT to standard postoperative stereotactic radiation therapy (SRT). Patients receiving TBRT experienced a recurrence rate of just 1.3% after one year, far lower than the 15.4% seen with SRT. This improvement is linked to the precise timing and placement of radiation, which targets residual cancer cells before they can regrow or develop resistance.

TBRT works by using thin, bioresorbable collagen tiles embedded with microscopic cesium-131 seeds. These tiles are placed in the tumour bed during surgery, delivering a continuous, localised dose of radiation. The design creates a steep dose gradient, meaning radiation is concentrated at the tumour site while sparing surrounding healthy brain tissue. This reduces neurotoxicity and lowers the risk of side effects like radiation necrosis, which occurred at similar rates in both TBRT and SRT groups.

Beyond reducing recurrences, TBRT also shortened treatment time dramatically. Patients underwent just one day of therapy after surgery, compared to 32 days with SRT. This allowed them to recover faster and resume other cancer treatments sooner. Median overall survival for the TBRT group reached 42.5 months—more than double the 17.6 months observed with standard SRT.

The trial’s success highlights how a technique originally used for other cancers has been adapted for the brain, a highly delicate organ. By delivering radiation directly to the tumour bed, TBRT minimises damage to healthy tissue while maximising effectiveness against residual disease. The findings suggest TBRT could become a preferred option for patients with brain metastases, offering both longer survival and fewer recurrences. Further research will track long-term tumour control, neurocognitive effects, and quality of life comparisons with existing radiation methods. For now, the trial marks a significant advance in targeted brain cancer treatment.